Effectiveness and Hepatotoxicity of Statins in Men Seropositive for Hepatitis C Virus
- 1 June 2007
- journal article
- Published by Wiley in Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
- Vol. 27 (6) , 845-851
Abstract
Study Objective. To evaluate the effectiveness and hepatotoxicity of statins in patients who are seropositive for hepatitis C virus (HCV).Design. Retrospective review of a registry of patients with HCVSetting. Veterans Affairs Medical Center.Patients. One hundred forty‐six male patients who were seropositive for HCV and had received statin therapy between January 1, 1995, and September 9, 2003.Measurements and Main Results. Demographic and clinical data were collected for each patient; lipid and alanine aminotransferase (ALT) levels at baseline (within 6 mo of starting a statin), at 3 and 6 months after starting a statin, and at long‐term follow‐up (mean 22 mo) were also recorded. The primary efficacy end point was a significant decrease from baseline to long‐term follow‐up low‐density lipoprotein cholesterol (LDL) level; the primary safety end point was a significant increase from baseline in ALT level. The mean change in LDL level was a reduction of 22% (pConclusion. In men seropositive for HCV, statins were effective in reducing LDL levels and did not result in significant increases in ALT levels from baseline. Thus, statin therapy should be considered for patients with HCV who are at risk for coronary heart disease and do not have significantly elevated serum transaminase levels at baseline.Keywords
This publication has 28 references indexed in Scilit:
- Incidence of Statin Hepatotoxicity in Patients With Hepatitis CClinical Gastroenterology and Hepatology, 2006
- An Assessment of Statin Safety by HepatologistsThe American Journal of Cardiology, 2006
- Final Conclusions and Recommendations of the National Lipid Association Statin Safety Assessment Task ForceThe American Journal of Cardiology, 2006
- Heart Disease and Stroke Statistics—2006 UpdateCirculation, 2006
- Experience With Statin Use in Patients With Chronic Hepatitis C InfectionThe American Journal of Cardiology, 2005
- ReplyGastroenterology, 2004
- Diagnosis, management, and treatment of hepatitis C†Hepatology, 2004
- The liver and lovastatinThe American Journal of Cardiology, 2002
- Comparative Dose Efficacy Study of Atorvastatin Versus Simvastatin, Pravastatin, Lovastatin, and Fluvastatin in Patients With Hypercholesterolemia (The CURVES Study) fn1fn1This study was supported by Parke-Davis, Division of Warner Lambert Company, Morris Plains, New Jersey. Manuscript received August 20, 1997; revised manuscript received and accepted November 24, 1997.The American Journal of Cardiology, 1998
- Detecting alcoholism. The CAGE questionnaireJAMA, 1984